论文部分内容阅读
目的对比分析宫颈环形电切术(LEEP)术后重组人干扰素α-2b阴道泡腾胶囊对宫颈高危型人乳头瘤病毒(HPV)感染患者的临床效果。方法 96例高级别宫颈上皮内瘤变LEEP术后宫颈高危型HPV持续阳性患者,随机分为对照组和观察组,各48例。观察组患者实施重组人干扰素α-2b阴道泡腾胶囊治疗,对照组患者未用药治疗。对比两组患者的临床效果。结果治疗前,观察组患者HPV感染率为64.6%,对照组为62.5%,比较差异无统计学意义(χ~2=0.04,P>0.05)。治疗后6个月,观察组患者HPV感染率为6.3%,低于对照组的22.9%,差异具有统计学意义(χ~2=5.35,P<0.05)。治疗后12个月,观察组患者HPV感染率为0,低于对照组的10.4%,差异具有统计学意义(χ~2=5.27,P<0.05)。结论重组人干扰素α-2b阴道泡腾胶囊用于LEEP术后宫颈高危型HPV感染的治疗,可以降低多重高危型HPV感染发生率,具有较高的临床价值,值得临床推广。
Objective To compare the clinical effects of recombinant human interferon α-2b vaginal effervescent capsules after cervical torotomy (LEEP) on patients with high-risk cervical papillomavirus (HPV) infection. Methods 96 cases of high-grade cervical intraepithelial neoplasia after high-risk cervical HPV type LEEP persistent HPV positive patients were randomly divided into control group and observation group, each 48 cases. Observation group of patients with recombinant human interferon α-2b vaginal effervescent capsules treatment, the control group of patients without medication. Compare the clinical effect of two groups of patients. Results Before treatment, HPV infection rate was 64.6% in the observation group and 62.5% in the control group, with no significant difference (χ ~ 2 = 0.04, P> 0.05). At 6 months after treatment, the HPV infection rate in the observation group was 6.3%, which was lower than that in the control group (22.9%). The difference was statistically significant (χ ~ 2 = 5.35, P <0.05). At 12 months after treatment, the HPV infection rate in the observation group was 0, which was lower than 10.4% in the control group, with statistical significance (χ ~ 2 = 5.27, P <0.05). Conclusions The use of recombinant human interferon α-2b vaginal effervescent capsules in the treatment of cervical high-risk HPV infection after LEEP can reduce the incidence of multiple high-risk HPV infection, and has high clinical value and worthy of clinical promotion.